|
Recorded Delivery ellipta vs spiriva Matisi's troubles began in mid-2012, when a financial commentator posted a remark on an online bulleting board stating that shares of a Arena had "climbed high" because of a widespread belief that the Food and Drug Administration would approve an obesity drug the company developed. She also cited the cautionary Barron's article.
|
